###### Key questions

What is already known about this subject?
=========================================

-   Heart failure with preserved ejection fraction (HFpEF) involves 50% of hospitalised patients with heart failure (HF).

-   Dyspnoea is *the* cardinal symptom of HF, but dyspnoea is frequently caused by non-cardiac comorbidity.

What does this study add?
=========================

-   The majority of previous studies did not examine consecutive patients with dyspnoea and did not base their HF diagnosis on natriuretic peptides and a comprehensive echocardiogram with evaluation of diastolic function.

-   In our prospective observational study, we asked, 'what is the diagnostic outcome of applying European Society of Cardiology (ESC) criteria including natriuretic peptide and a comprehensive echocardiogram to consecutive patients admitted with dyspnea?'.

-   The echocardiogram showed cardiac dysfunction, and therefore HF, in 90% of patients admitted with dyspnoea and elevated NT-proBNP, where 41% had HFpEF, and 10% HF with EF 40%--49%. However, pulmonary disease was the predominant adjudicated clinical diagnosis in patients who fulfilled contemporary echocardiographic criteria for HFpEF.

How might this impact on clinical practice?
===========================================

-   This study supports that HF is a frequent complication in pulmonary disease, and we show the outcome of using the 2016 ESC guideline strategy to identify HF in consecutive patients admitted with dyspnoea.

-   Although HFmrEF and HFpEF subtypes accounts for half of all HF, 9 out of 10 have significant non-cardiac disease as the predominant adjudicated problem, which calls for a multidisciplinary management plan and more research addressing this particular problem.

Introduction {#s1}
============

Heart failure with preserved ejection fraction (HFpEF) involves 50% of hospitalised patients with heart failure (HF),[@R1] but evaluation of the scale of the problem varies due to unclear diagnostic criteria,[@R2] comorbidity and various types of hospitals.[@R1] Previous registry studies of HF epidemiology were not based on comprehensive echocardiograms, and they rarely describe the underlying subtype of HF. Knowing the subtype of HF is essential for selecting evidence-based treatment, but there seems to be a mismatch between patients entering randomised clinical trials and patients seen in clinical practice.[@R3]

Recent guidelines authorise the use of natriuretic peptide to rule out HF[@R4]; they acknowledge left ventricular (LV) hypertrophy and enlarged left atrium (LA) as a reason for HFpEF and give clear criteria for diastolic dysfunction.[@R4] The doorway to finding patients with HF is to examine patients with dyspnoea, and therefore, we asked, 'what is the diagnostic outcome of applying novel guideline criteria including a comprehensive echocardiogram to consecutive patients admitted with dyspnea?'.

We used a prospective observational study to describe the subtype of cardiac dysfunction, if any, among all comers admitted with dyspnoea. Although data were collected in 2010,[@R6] the recent 2016 guidelines were used to diagnose HFpEF and 'HFmrEF'[@R4] (midrange LV EF from 40% to 49%). The aim was to describe the frequency of subtypes of cardiac dysfunction in patients hospitalised with dyspnoea and elevated NT-proBNP, in relation to HFpEF, HFmrEF and HF due to reduced EF (HFrEF) and to examine the impact of non-cardiac comorbidity.

Methods {#s2}
=======

Study design and population {#s2-1}
---------------------------

The Copenhagen Heart Failure with Preserved Ejection Fraction study was designed as a prospective observational study to evaluate all patients ≥40 years of age admitted with acute dyspnoea to the acute medical unit, general medicine ward and department of cardiology at Bispebjerg University Hospital, a non-tertiary hospital serving about 250 000 people in 2010. Patients from the accidents and emergency department were examined only if they were subsequently hospitalised. Screening was performed at 180 predefined randomly selected study days between 16 November 2009 and 31 July 2011, covering all days of the week.

The Danish regional ethical committee waived requirement for informed consent because NT-proBNP measurement and echocardiography were considered appropriate examinations and the study was classified as a prospective registry.

Patients were identified by a research fellow in cardiology (CMC) who screened all medical records within the first 24 hours after non-elective admission. The research fellow verified data from the clinically working physicians and collected supplementary baseline data including previous and presumptive diagnoses (see [figure 1](#F1){ref-type="fig"}).

![Consort diagram of patients. eGFR, estimated glomerular filtration rate; HF, heart failure.](openhrt-2018-000928f01){#F1}

Inclusion criteria and presumptive cause of dyspnoea {#s2-2}
----------------------------------------------------

Patients were eligible if dyspnoea (any sensation of shortness of breath, resting dyspnoea, orthopnoea or paroxysmal nocturnal dyspnoea) or suspected HF was the dominant or codominant reason for admission. The initial presumptive causes of dyspnoea, as made by the staff physicians within 24 hours, were systematically reviewed by the research fellow and categorised into: (1) non-cardiac dyspnoea or (2) presumptive cardiac dyspnoea based on the following criteria.

### Non-cardiac dyspnoea {#s2-2-1}

-   Patients presenting with obvious non-cardiac conditions: known irreversible intractable chest malignancy, previous admissions with documented severe chronic obstructive pulmonary disease (COPD) and forced expiratory volume \<50% of expected value in an outpatient setting, previous COPD admission with need of home oxygen prior to admission, acute pneumonia documented on X-ray, or acute pulmonary embolism, severe anaemia (haemoglobin \<5 mmol/L) or severe obesity (body mass index \>40).

### Presumptive cardiac dyspnoea {#s2-2-2}

-   Remaining patients were classified as presumptive cardiac dyspnoea, also including dyspnoea of unknown aetiology ([figure 1](#F1){ref-type="fig"}).

Exclusion criteria {#s2-3}
------------------

Patients were excluded if they had chronic kidney disease stage 4 and 5 with an estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² using the Modification of Diet in Renal Disease formula, or if they had predominantly chest pain with acute coronary syndrome and scheduled for an acute coronary angiogram. Patients with presumptive non-cardiac dyspnoea were excluded if NT-proBNP was under the below mentioned age-adjusted rule-in values.

NT-proBNP analysis {#s2-4}
------------------

NT-proBNP was analysed at time of admission using a commercially available immunoassay (Elecsys NT-proBNP, Roche Diagnostics, pmol/L) on the Cobas e 411 platform. Our laboratory reports an inter-run coefficient of variation \<2.0%. The rule out threshold was NT-proBNP concentration \<35 pmol/L, equal to 296 ng/L (to convert ng/L to pmol/L, multiply by 0.118).[@R7] Patients with presumptive non-cardiac dyspnoea were excluded if NT-proBNP \<50 pmol/L (423 ng/L) for age 40--49 years; \<100 pmol/L (846 ng/L) for age 50--74 years; and \<200 pmol/L (1691 ng/L) for age 75 years or more. These values are slightly lower than the age adjusted rule-in values of 450 ng/L, 900 ng/L and 1800 ng/L that were previously recommended for the respective age groups.[@R7]

Echocardiogram {#s2-5}
--------------

A comprehensive echocardiogram was performed by the cardiology fellow in all included patients ([figure 1](#F1){ref-type="fig"}) within 48 hours of admission, unless an echocardiogram within the last 3 months existed and documented an left ventricular ejection fraction (LVEF) \<40% or severe valvular heart disease (VHD). The echocardiogram included systematic evaluation of cardiac structure and function,[@R9] and all patients with LVEF of 40% or above were examined for diastolic dysfunction.[@R10] Measurements equalled the median over 3--5 cardiac cycles when patients had sinus rhythm and median over 5--10 cycles for patients in atrial fibrillation (AF).

LVEF and severe valve disease were reported to the clinical staff promptly, but remaining parameters were analysed later on stored images (Xcelera system by Philips). Validation of the individual echocardiographic parameters was performed by a second reviewer (OWN and/or LK). LA maximum volume was calculated in four-chamber and two-chamber view using the area length formula.[@R12] Key structural alterations were defined as: LA maximum volume index \>34 mL/m^2^ and LV hypertrophy, defined as LV mass index ≥115 g/m^2^ for males and ≥95 g/m^2^ for females.[@R4] For the present analyses, we defined 'definite diastolic dysfunction' according to a recent consensus paper[@R5] as the presence of 3 or 4 of the following four parameters: velocity of septal e′ \<7 cm/s or lateral e′ \<10 cm/s; average E/e′ ratio \>14; LA maximum volume index \>34 mL/m^2^; peak TR velocity \>2.8 m/s. e′ was calculated as the mean from anterior, posterior, septal and lateral walls.

ESC classification of HF subtypes {#s2-6}
---------------------------------

Evidence for abnormal cardiac function or structure were classified according to 2016 ESC criteria,[@R4] where severe VHD was classified first to avoid interference of VHD with subsequent grouping. Hence, cardiac dysfunction was classified in the ranked order:

1.  First, in case of severe VHD, patients were classified as 'HFvhd'.

2.  The remaining with LVEF \<40% were denoted HF with reduced EF, that is, 'HFrEF'.

3.  The remaining with LVEF from 40% to 49% were classified as 'HFmrEF'.

4.  The remaining with LVEF [\>]{.ul}50% who had 'definite diastolic dysfunction', LA enlargement or LV hypertrophy were denoted as 'HFpEF'.

5.  The rest with LVEF [\>]{.ul}50% and 'indeterminate or no definite LV diastolic dysfunction' were denoted as 'not HF'.

Clinical scores of HF signs and comorbidity {#s2-7}
-------------------------------------------

The research fellow documented all subjective and objective signs and symptoms needed for the Framingham and Boston heart failure score.[@R13] The Boston HF score adds signs and symptoms into a score from 0 to 12 where 0--4 denote 'unlikely HF', 5--7 denote 'possible HF' and 8--12 denote 'definite HF'. The Charlson Comorbidity Index was calculated as the total of the patient's comorbid conditions, which had been weighted without giving weight to age.[@R15]

Adjudicated primary diagnosis {#s2-8}
-----------------------------

Acute decompensated HF (ADHF) was adjudicated as the primary diagnosis if ADHF had been the most significant problem during admission based on review of medical records, staff diagnoses and echocardiography. The adjudicated diagnosis required consensus among the clinical working cardiologists and the research fellow in cardiology. In case of inconsistency or doubt, the final diagnosis was further adjudicated by additional two cardiologists (OWN and LK). To minimise the ambiguity of clinical judgement, the definition of ADHF relied on documentation of central or peripheral fluid retention as the most significant clinical problem, with an adequate response to diuretic therapy, accompanied by abnormal function or structure in the reviewed echocardiogram. Reversible reasons for acute decompensation such as arrhythmias or abnormal loading conditions were also considered valid reasons for ADHF.

Statistics {#s2-9}
----------

Values are expressed as means and SD, medians and quartiles or counts and percentages as appropriate in relation to normality.

Participants with missing values were minimised by adhering to the inclusion and exclusion criteria. No imputation was made for participants with missing values, but data validity was ensured by reporting variables for subgroups with a high rate of non-missing values (see [online supplementary table](#SP1){ref-type="supplementary-material"} for missing values). Sensitivity analyses were inherently performed for patients with and without cardiac dyspnoea and by comparing diastolic function to patients with 'No HF'. NT-proBNP was transformed with the natural logarithm before comparing mean values in trend analyses. Univariate analyses of variables between groups were performed with the Kruskall-Wallis test and non-parametric test for trend examined trends between groups. P\<0.05 was taken to indicate significance and all statistical analyses were performed using Stata V.13 statistical software.

10.1136/openhrt-2018-000928.supp1

Results {#s3}
=======

Population {#s3-1}
----------

Seven hundred and seven patients with dyspnoea were eligible during 180 days of screening, after excluding 57 patients due to chronic kidney disease and 191 with low NT-proBNP values ([figure 1](#F1){ref-type="fig"}). The 191 patients excluded because of low NT-proBNP had a mean age of 62.7 (SD 12.6) years, eGFR of 80.9 (SD 14.5), NT-proBNP of 129 (SD 68) ng/L, 57% had COPD/asthma and 2.7% AF. Of 164 patients with presumptive non-cardiac dyspnoea, we excluded 89 who had NT-proBNP below the age-adjusted rule-in values. Hence, a total of 370 patients were included of whom 295 patients had presumptive cardiac dyspnoea and 75 had presumptive non-cardiac dyspnoea ([figure 1](#F1){ref-type="fig"}). Significant signs or symptoms of HF related to more than 90% of patients, as indicated by a Boston score above 4 points. ([table 1](#T1){ref-type="table"})

###### 

Characteristics of patients according to presumptive working diagnosis

                                                                       Presumptive cardiac dyspnoea   Presumptive non-cardiac dyspnoea   P value
  ------------------------------------------------ ------------------- ------------------------------ ---------------------------------- ---------
  N                                                                    295                            75                                 
  Age, mean (SD)                                   77.0 (11.9)         72.9 (10.9)                    0.007                              
  Female gender                                                        145 (49.2%)                    43 (57.3%)                         0.21
  Previous hosp for HF                                                 98 (33.2%)                     7 (9.3%)                           \<0.001
  Known valve disease                                                  36 (12.2%)                     2 (2.7%)                           0.015
  Known HFrEF                                                          56 (19.0%)                     0 (0.0%)                           \<0.001
  IHD                                                                  76 (25.8%)                     12 (16.0%)                         0.076
  Diabetes                                                             61 (20.7%)                     16 (21.3%)                         0.90
  COPD                                                                 91 (30.8%)                     51 (68.0%)                         \<0.001
  Atrial fibrillation, history or new              150 (50.8%)         27 (36.0%)                     0.022                              
  Hypertension, history or [\>]{.ul}140/90 mm Hg   216 (73.2%)         47 (62.7%)                     0.072                              
  Anaemia (HgB \<8.1 M or \<7.4 F)                 116 (39.3%)         39 (52.0%)                     0.047                              
  *Chronic kidney disease*                         ≥90                 46 (15.7%)                     13 (17.3%)                         0.86
  *Groups from eGFR*                               60--89              127 (43.3%)                    30 (40.0%)                         
                                                   30--59              120 (41.0%)                    32 (42.7%)                         
  NT-proBNP, median (IQR), ng/L                    3102 (1322, 8729)   2712 (1686, 9034)              0.74                               
  Charlson Comorbidity Index, mean (SD)            2.5 (1.9)           3.1 (2.3)                      0.023                              
  *Signs and symptoms of HF on examination*                                                                                              
  *Boston score*                                   0--4 point          30 (10.2%)                     3 (4.0%)                           0.005
                                                   5--7 point          83 (28.1%)                     35 (46.7%)                         
                                                   8--12 point         182 (61.7%)                    37 (49.3%)                         
  Framingham HF                                    Negative            100 (33.9%)                    42 (56.0%)                         \<0.001
                                                   Positive            195 (66.1%)                    33 (44.0%)                         

COPD, chronic obstructive pulmonary disease;HF, heart failure; HFrEF, heart failure due to reduced EF; IHD, ischaemic heart disease; eGFR, estimated glomerular filtration rate.

HF subtypes in examined patients {#s3-2}
--------------------------------

No cardiac dysfunction was found in 10% of included patients ([figures 1and and 2](#F1 F2){ref-type="fig"}) (38/370, 95% CI 7% to 13%), with similar rates for presumptive non-cardiac and cardiac dyspnoea (13.5% vs 9%, ns.). Among 332 patients with cardiac dysfunction, 10.2% had HFmrEF (34/332, 95% CI 7% to 14%) and 41% HFpEF (137/332, 95% CI 35% to 47%). HFpEF was twice as common in patients with presumptive non-cardiac dyspnoea as compared with presumptive cardiac dyspnoea (70.8% vs 34.1%, p\<0.0001, [figure 3](#F3){ref-type="fig"}). Of the 62 patients with severe valve disease, 42% (26/62, 95% CI 20% to 54%) also had LVEF \<40%.

![Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular heart disease (n=61), HFrEF is HF with reduced ejection fraction (n=100), HFprEF is HF with mid range ejection fraction (n=34) and HFpEF is HF with preserved ejection fraction (n=137). EF, ejection fraction; HF, heart failure; HFmrEF, HF due to midrange EF; HFpEF, HF with preserved EF; HFrEF, HF due to reduced EF.](openhrt-2018-000928f02){#F2}

![Percentage distribution of ESC types of cardiac dysfunction among 65 patients with presumptive non-cardiac dyspnoea: HFvhd (n=4); HFrEF (n=11), HFmrEF (n=4) and HFpEF (n=46), and 267 HF patients with presumptive cardiac dyspnoea: HFvhd (n=57); HFrEF (n=89), HFmrEF (n=30) and HFpEF (n=91). EF, ejection fraction; HF, heart failure; HFmrEF, HF due to midrange EF; HFpEF, HF with preserved ejection fraction; HFrEF, HF due to reduced EF; HFvhd, HF due to valvular disease.](openhrt-2018-000928f03){#F3}

Patients characteristics in relation to HF subtype {#s3-3}
--------------------------------------------------

Moving from HFrEF over HFmrEF to HFpEF there was a significant trend for higher age, more females, lower diastolic BP, higher pulse pressure and lower NT-proBNP ([table 2](#T2){ref-type="table"}). HFmrEF was comparable with HFrEF in most aspects, apart from less comorbidity and a higher age in HFmrEF patients. HFmrEF was associated with significantly more of AF and ischaemic heart disease as compared with HFpEF.

###### 

Characteristics of HFrEF, HFmrEF and HFpEF

  ---------------------------------------------------------------------------------------------------------
  Characteristic                                   HFrEF           HFmrEF         HFpEF           P value
  ----------------------------------- ------------ --------------- -------------- --------------- ---------
  Age, mean (SD)                      Mean (SD)    73.2 (11.6)     77.2 (12.0)    77.1 (11.3)\*   0.021

  Male, n (%)                         Mean (SD)    71 (71.0%)      19 (55.9%)†    43 (31.4%)\*    \<0.001

  Body mass index, mean (SD)          Mean (SD)    26.3 (4.9)      28.8 (7.8)     26.7 (6.2)      0.923\
                                                                                                  0

  Heart rate per min                  Mean (SD)    93.9 (26.8)     92.3 (26.8)    92.8 (22.2)     0.896

  BP systolic, mm Hg                  Mean (SD)    140.9 (31.2)    143.9 (28.0)   143.5 (29.3)    0.326

  BP diastolic, mm Hg                 Mean (SD)    83.1 (22.0)     80.6 (20.6)    75.1 (16.5)\*   0.008

  Pulse pressure, mm Hg               Mean (SD)    57.8 (22)       63.3 (21.2)    68.1 (21.4)\*   \<0.001

  Respiratory rate, per min           Mean (SD)    23.4 (7.3)      21.8 (5.4)     23.4 (6.8)      0.656

  NT-proBNP, ng/L                     Mean (SD)    8700 (8701)     6151 (7598)†   2987 (3392)\*   \<0.001

  *NT-proBNP in intervals*            0--422       1 (1.0%)        0 (0.0%)       9 (6.6%)\*      \<0.001

  *Groups ng/L*                       423--845     4 (4.0%)        4 (11.8%)      11 (8.0%)        

                                      846--1690    10 (10.0%)      8 (23.5%)      34 (24.8%)       

                                      1691+        85 (85.0%)      22 (64.7%)     83 (60.6%)       

  *Clinical signs of heart failure*                                                                

   Dyspnoea at rest                   Number (%)   42 (42.0)       12 (35.3)      74 (54.0)       0.057

   Functional dyspnoea                Number (%)   86 (86.0)       30 (88.2)      126 (92.0)      0.140

   Dyspnoea when walking stairs       Number (%)   99 (99.0)       33 (97.1)      133 (97.1)      0.331

   Rales on auscultation              Number (%)   51 (51.0)       14 (41.2)      62 (45.3)       0.405

   Rhonchi on auscultation            Number (%)   23 (23.0)       7 (20.6)†      60 (43.8)\*     0.001

   Congestion on chest X-ray          Number (%)   41 (41.0)‡      5 (14.7)       28 (20.4)\*     0.001

  *Echocardiography*                                                                               

   LVEF %                             Mean (SD)    27.4 (7.4)‡     44.0 (2.8)†    58.5 (5.7)\*    \<0.001

   LV mass index,                     Mean (SD)    117.7 (31.3)‡   97.4 (20.6)†   87.8 (23.0)\*   \<0.001

   LA volume index, mL/m^2^           Mean (SD)    59.6 (16.0)     58.7 (20.4)†   51.8 (15.9)\*   0.001

   IVSd (cm)                          Mean (SD)    1.1 (0.2)       1.1 (0.2)†     1.0 (0.2)       0.206

   LVDd (cm)                          Mean (SD)    5.5 (0.7)‡      5.0 (0.7)†     4.6 (0.6)\*     \<0.001

   PWTd (cm)                          Mean (SD)    1.0 (0.2)       0.9 (0.2)      0.9 (0.2)\*     0.003
  ---------------------------------------------------------------------------------------------------------

\*P\<0.05 for individual comparison: HFrEF versus HFpEF.

†P\<0.05 for individual comparison: HFmrEF versus HFpEF.

‡P\<0.05 for individual comparison: HFrEF versus HFmrEF.

BP, blood pressure; EF, ejection fraction; HF, heart failure; HFmrEF, HF due to midrange EF; HFpEF, HF with preserved EF; HFrEF, HF due to reduced EF; IVSd, interventricular septum in diastole; LA, left atrium; LV, left ventricular; LVDd, left ventricular diameter in diastole; PWTd, posterior wall thickness in diastole.

Acute decompensated HF was adjudicated as the primary clinical diagnosis in 80% of HFrEF, 62% of HFmrEF and 27.7% of HFpEF ([figure 4](#F4){ref-type="fig"} and [table 3](#T3){ref-type="table"}). Similarly, pulmonary disease was the most frequent adjudicated primary clinical diagnosis in patients classified as HFpEF ([table 3](#T3){ref-type="table"}).

![The adjudicated primary diagnosis (HF, pneumonia, COPD or other) that dominated during admission according to ESC HF type: HFrEF (n=100), HFmrEF (n=34) and HFpEF (n=137). EF, ejection fraction; HF, heart failure; HFmrEF, HF due to midrange EF; HFpEF, HF with preserved EF; HFrEF, HF due to reduced EF.](openhrt-2018-000928f04){#F4}

###### 

Characteristics of HFrEF, HFmrEF and HFpEF

  Supplementary characteristics                 HFrEF        HFmrEF         HFpEF         P value
  --------------------------------- ----------- ------------ -------------- ------------- ---------
  *Adjudicated primary diagnosis*                                                         
   Decompensated HF                             80 (80.0%)   21 (61.8%)\*   38 (27.7%)†   \<0.001
    Pneumonia                                   10 (10.0%)   6 (17.6%)      41 (29.9%)    
     COPD                                       4 (4.0%)     2 (5.9%)       35 (25.5%)    
     Other                                      6 (6.0%)     5 (14.7%)      23 (16.8%)    
   *NT-proBNP in intervals*         0--422      1 (1.0%)     0 (0.0%)       9 (6.6%)†     \<0.001
    *groups ng/L*                   423--845    4 (4.0%)     4 (11.8%)      11 (8.0%)     
                                    846--1690   10 (10.0%)   8 (23.5%)      34 (24.8%)    
                                    1691+       85 (85.0%)   22 (64.7%)     83 (60.6%)    
  Chronic kidney disease                                                                  
   Stage 1 with eGFR                80+         14 (14.1%)   4 (11.8%)      23 (16.8%)    0.423
   Stage 2 with eGFR                60--79      38 (38.4%)   18 (52.9%)     56 (40.9%)    
   Stage 3 with eGFR                30--59      47 (47.5%)   12 (35.3%)     58 (42.3%)    
  *Echocardiography*                                                                      
   IVSd (cm)                        Mean (SD)   1.1 (0.2)    1.1 (0.2)\*    1.0 (0.2)     0.206
   PWTd (cm)                        Mean (SD)   1.0 (0.2)    0.9 (0.2)      0.9 (0.2)†    0.003

\*HFmrEF with HFpEF.

†HFrEF with HFpEF.

‡HFrEF with HFmrEF.

EF, ejection fraction; HF, heart failure; HFmrEF, HF due to midrange EF; HFpEF, HF with preserved EF; HFrEF, HF due to reduced EF; IVSd, interventricular septum in diastole; PWTd, posterior wall thickness in diastole.

HFpEF without a non-cardiac adjudicated primary diagnosis related to just 11% (38/332) of all patients fulfilling the ESC criteria for HF (n=38 with ADHF in [table 3](#T3){ref-type="table"}).

Diastolic dysfunction in patients with LVEF of 40% or more {#s3-4}
----------------------------------------------------------

'Definite' diastolic dysfunction was observed in 62% of HFmrEF and 60% of HFpEF based on diastolic function parameters ([table 4](#T4){ref-type="table"}), while 'normal' diastolic function comprised less than 10% in HFmrEF and HFpEF. More than 95% of HFmrEF and HFpEF patients had enlarged LA. Indeterminate diastolic dysfunction was observed in about one-third of all subtypes including the 'no HF' group ([table 4](#T4){ref-type="table"}).

###### 

Characteristics of all patients with LVEF of 40% or more in relation to cardiac dysfunction type HFmrEF, HFpEF and no dysfunction (no HF)

  ---------------------------------------------------------------------------------------------------
  Characteristics                          LVEF 40--49    LVEF [\>]{.ul}50%   P value       
  ---------------------------------------- -------------- ------------------- ------------- ---------
  Age, mean (SD)                           77.2 (12.0)    77.1 (11.3)         72.9 (11.6)   0.110

  Male, n (%)                              19 (55.9)      43 (31.4)           16 (42.1)     0.275

  NT-proBNP ng/L, median (IQR)             3496\          2008\               996\          \<0.001
                                           (1246--6797)   (1161--3356)        (551--3729)   

  *Presumptive reason for dyspnoea*                                                         

   Cardiac dyspnoea                        30 (88.2%)     91 (66.4%)          28 (73.7%)    0.207

   Non-cardiac dyspnoea                    4 (11.8%)      46 (33.6%)          10 (26.3%)    

   eGFR, mean (SD)                         62.8 (23.6)    67.5 (25.4)         83.4 (31.4)   0.002

   Charlson Comorbidity Index, mean (SD)   2.3 (1.8)      2.5 (2.1)           1.6 (1.3)     0.106

   Boston score, median (IQR)              7.5 (5, 9)     7 (6, 9)            7.5 (7, 8)    0.737

   Framingham HF positive                  21 (61.8%)     65 (47.4%)          14 (36.8%)    0.036

  *Echocardiography, structural values*                                                     

   IVSd (cm), mean (SD)                    1.1 (0.2)      1.0 (0.2)           0.9 (0.2)     \<0.001

   LVDd (cm), mean (SD)                    5.0 (0.7)      4.6 (0.6)           4.2 (0.5)     \<0.001

   LA vol index, mean (SD) mL/m^2^         58.7 (20.4)    51.8 (15.9)         27.4 (4.4)    \<0.001

   LV mass index, mean (SD)                97.4 (20.6)    87.8 (23.0)         63.6 (11.5)   \<0.001

   LV hypertrophy                          8 (25.0%)      32 (26.4%)          0 (0.0%)      0.001

  *Diastolic dysfunction, four criteria*                                                    

   LA volume index ≥34 mL/m^2^ BSA         31 (91.2%)     131 (95.6%)         0 (0.0%)      \<0.001

   TR velocity ≥2.8 m/s                    15 (60%)       65 (68%)            14 (52%)      0.512

   E/e′\>14                                18 (52.9%)     59 (43.1%)          5 (13.2%)     \<0.001

   e′ reduced                              32 (94.1%)     119 (86.9%)         31 (81.6%)    0.116

  *Diastolic function, grading*                                                             

   Normal (0 or 1 criteria)                2 (5.9%)       12 (8.8%)           23 (60.5%)    \<0.001

   Indeterminate (exactly 2 criteria)      11 (32.4%)     43 (31.4%)          15 (39.5%)    

   Definite abnormal (3 or 4 criteria)     21 (61.8%)     82 (59.9%)          0 (0.0%)       
  ---------------------------------------------------------------------------------------------------

BSA, body surface area;EF, ejection fraction; HF, heart failure; HFmrEF, HF due to midrange EF; HFpEF, HF with preserved EF; HFrEF, HF due to reduced EF; IVSd, interventricular septum in diastole;LA, left atrium; LVDd, left ventricular diameter in diastole;TR, Tricuspid regurgitation; eGFR, estimated glomerular filtration rate; LA vol index, left atrium volume index.

Discussion {#s4}
==========

Cardiac dysfunction according to contemporary ESC criteria for HF was demonstrated in 90% of consecutive hospitalised patients with dyspnoea and elevated NT-proBNP, where 41% could be ascribed to HFpEF and 10% to HFmrEF. Presumed non-cardiac dyspnoea and elevated NT-proBNP was associated with a 71% prevalence of HFpEF, and the diagnosis primarily grounded on structural rather than functional abnormalities since 40% of HFpEF patients lacked 'definite diastolic dysfunction'. HFpEF presenting as ADHF accounts for merely 11%, not 41%, since pulmonary disease was the predominant adjudicated problem in patients with HFpEF.

HF criteria in clinical studies {#s4-1}
-------------------------------

Our study differs from other studies by examining consecutive patients with undifferentiated dyspnoea, instead of just patients with presumptive cardiac dyspnoea. By use of the contemporary 2016 ESC criteria for HF and diastolic dysfunction, merely 10% did not have one of the ESC HF subtypes, which is unprecedented information.

The ESC criteria for cardiac dysfunction are objective and externally valid.[@R4] However, it may be questioned whether LA enlargement and/or LV hypertrophy alone may account for hospitalised HFpEF, because both findings are highly prevalent in elderly patients with hypertension and/or AF. In a recent community-based study, 49% of patients had one or two abnormal measures of diastolic dysfunction.[@R17] Although LA enlargement and LV hypertrophy do not cause HF per se, they predispose to the symptoms and signs of HF by reducing the patients ability to compensate when the cardiovascular system become challenged.[@R18]

A causal relationship between dyspnoea and HFpEF is more convincing if three or four out of four diastolic dysfunction criteria are abnormal.[@R5] However, diastolic dysfunction parameters are dynamic, and the E/e′ and tricuspid regurgitant velocity vary in relation to LV filling pressure, so timing of echocardiography becomes important. In this study, echocardiography was made within 48 hours of admission, and the Doppler signs of diastolic dysfunction probably diminished in some patients after appropriate treatment.

ESC subtypes of HF {#s4-2}
------------------

HFmrEF occurred in 10%, which is lower than previous estimates of 10%--20%,[@R19] probably because we classified severe valve disease before all the other subtypes. HFmrEF patients had a higher burden than HFpEF with respect to AF, ischaemic heart disease and ADHF as the adjudicated primary clinical diagnosis. Just 5.9% of HFmrEF patients had a normal diastolic function, indicating that HFmrEF patients have a significant cardiac dysfunction.

Although one out of two patients had a LVEF above 40%, at most 1 in 10 could be considered for a clinical trial evaluating new therapy for HFpEF, calculated as an overall 41.3% prevalence of HFpEF ([figure 2](#F2){ref-type="fig"}) of whom 27% were adjudicated to have ADHF (see [figure 4](#F4){ref-type="fig"}).

Use of natriuretic peptides to diagnose HF {#s4-3}
------------------------------------------

Guidelines recommend NT-proBNP screening in patients presumed to have HF, where a value below 300 ng/L rules out HF. However, guidelines are indecisive regarding routine use of NT-proBNP testing in patients with presumptive non-cardiac dyspnoea and recent clinical trials of acute HF included patients based on much higher NT-proBNP values, above 2000 pg/mL.[@R20]

Our results support that an echocardiogram including evaluation of diastolic function is indicated if NT-proBNP is elevated above the here applied threshold values. A recent study of 80+ year old patients from Singapore and New Zealand showed that similar rule-in values had a sensitivity of 89% and negative predictive value of 94%.[@R22]

Problems with diagnosing HF {#s4-4}
---------------------------

The high frequency of comorbidities in consecutive patients with dyspnoea precludes the idea of assigning an 'exclusive' HF diagnosis as the undisputed cause of dyspnoea, and there is an unmet need for guidelines and clinical trials of HF to address this problem. It is well known that comorbidity begets HF, and comorbidity is much more than an innocent bystander to HF. The mechanisms for pulmonary disease to interact with HFpEF could be through a decreased cardiorespiratory reserve[@R18] secondary to systemic inflammation, endothelial dysfunction, increasing load on the peripheral as well as the pulmonic vasculature which lead to higher LV filling pressure, abnormal diastolic function parameters[@R23] and pulmonary hypertension. However, there is also a risk that the contemporary diagnostic criteria will 'overdiagnose' HFpEF in patients with preexisting asymptomatic left atrial enlargement[@R24] or LV hypertrophy.

Strengths and limitations {#s4-5}
-------------------------

The main advantage of the present study is that the HFpEF diagnosis was evaluated in a large population based on a comprehensive echocardiogram instead of the more widely used incomplete criterion 'lack of an echocardiogram showing a low EF'. Unlike most other studies, we examined consecutive patients and did a systematic prospective work-up in every patient with dyspnoea including a comprehensive echocardiogram and a careful validation in each patient in relation to competing comorbidities. Large registry studies of hospitalised patients with HF do not provide this type of information.

Clinical research in the emergency setting is challenging with a lot of pitfalls, but it is the only way to characterise acute real-world patients presenting with a plethora of presumptive diagnoses. We could not entirely avoid selection bias and excluded stage 4 and 5 kidney disease, because severe kidney disease is known to increase NT-proBNP and induce congestion, and this entity should be subject for a separate investigation.[@R25] Our data also do not reflect patients presenting with acute coronary syndrome, critically acute patients who died, were transferred or trivial cases with mild symptoms that were discharged immediately from the emergency room.

Generalisability of our results may not apply to other healthcare systems who have a different level of threshold to admit patients. It is also a limitation that our data are obtained in a single centre, but transferability of our results may be ensured by using the same objective selection criteria based on NT-proBNP, acute coronary syndrome and renal dysfunction.

Implication {#s5}
===========

This study reflects what would be the outcome of making a comprehensive examination in consecutive hospitalised patients with dyspnoea and elevated NT-proBNP. Current guidelines already recommend natriuretic peptide testing and/or echocardiography in hospitalised patients with suspected acute HF.[@R4] However, the overwhelming problem is 'when to suspect heart failure' among the many hospitalised patients with unclear signs and symptoms. This study supports making a comprehensive echocardiogram in all patients presenting with dyspnoea and elevated NT-proBNP disregard of presumptive cause of dyspnoea although using differential NT-proBNP threshold values. Our study also indicates that a new hypothetical drug for 'essential' HFpEF may only be applicable to about 1 in 10 patients hospitalised for HF, meaning that a diagnostic and therapeutic dilemma still exists for the majority of patients who fulfil echocardiographic criteria for HFpEF. It is not known if such patients would benefit from a cardiologist advice, and there are ongoing trials to examine if prognosis of HFpEF can be improved by use of a multidisciplinary integrated care management.[@R26]
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